D-0419-2026 Class II Ongoing

Recalled by Appco Pharma LLC — Piscataway, NJ

FDA drug recall D-0419-2026 was initiated by Appco Pharma LLC on Mar 27, 2026 and is designated Class II. Reason for recall: cGMP deviation: detection of Nitrosamine Drug Substance-Related Impurities, N-nitroso-prazosin impurity C (NNP) above acceptable limits. The recall status is ongoing. Affected quantity: 88,008 bottles- 100's count.

Recall details

Product Type
Drugs
Report Date
Apr 8, 2026
Initiation Date
Mar 27, 2026
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
88,008 bottles- 100's count

Product description

Prazosin Hydrochloride Capsules, USP, 1mg, 100-count bottle, Rx Only, Manufactured for: Biocon Pharma Inc., Iselin, NJ, Manufactured by: Appco Pharma LLC, Piscataway, NJ, NDC 70377-066-11.

Reason for recall

cGMP deviation: detection of Nitrosamine Drug Substance-Related Impurities, N-nitroso-prazosin impurity C (NNP) above acceptable limits.

Distribution pattern

U.S.A. Nationwide

Code information

Lot:2404160C, Exp.:2026/MAR; 2406253C, Exp.:2026/MAY; 2407311C, Exp.: 2026/JUL; 2407312C, Exp.:2026/JUL; 2408350C, Exp.:2026/JUL; 2505172C, Exp.:2027/MAY; 2506191C, Exp.: 2027/JUN.

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0419-2026
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0419-2026. Report a data issue: hello@regdatalab.com.